Lecture 12 - pharmacogenomics Flashcards
describe genetic differences and impact on drugs
genetic differences in the DNA of our genes can change our pharmacokinetics (how our body process a drug) and pharmacodynamics (how a drug affects our body)
what is personalised or stratified medicine?
when we look at a patients DNA and determine how they will respond well to a drug treatment and avoid prescribing drugs that might provoke an adverse reaction or death
what are adverse drugs reactions often mediated to changes by ?
cytochrome P450 metabolising enzymes
Human Leukocyte Antigen HLA profile: how the body distinguishes ‘self’ form ‘non-self’ and so may play a role in how drugs trigger inappropriate immune response
drug transporters - how the drug enters or remain within the cells
Give examples of where pharmacogenomics is used in routine
- Avoiding serious adverse effects associated with fluoropyrimidine chemotherapy of certain cancers
- Avoiding abacavir hypersensitivity syndrome (AHS) in the treatment of HIV
3.Avoiding carbamazepine adverse effects, Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in treatment of epilepsy and bipolar disorder. - Testing patients for response to clopidogrel to avoid risk of stroke
Which gene is tested before prescribing fluoropyrimidine chemotherapy like 5-FU?
The DPYD gene.
What is the function of the enzyme DPD?
it breaks down 5-FU into tolerable less toxic metabolites.
What happens in DPYD deficiency?
5-FU accumulates, leading to severe off-target toxicity.
What is Abacavir used for?
abacavir is a nucleoside reveres transcriptase inhibitor used to stop HIV
What syndrome can Abacavir cause in susceptible patients?
Abacavir Hypersensitivity Syndrome (AHS). HLA-B*57:01 allele is associated with AHS
What is Carbamazepine used for?
treating epilepsy and bipolar disorder.
Which HLA allele is linked to serious ADRs from carbamazepine in SE Asians?
A: HLA-A*15:02
what does clopidogrel do and why is it considered a pro drug ?
Prevents blood clots by inhibiting platelets. It must be activated by the CYP2C19 enzyme
What happens if someone has a poor-metabolizer CYP2C19 variant?
the drug is ineffective → risk of stroke remains.